SignatureFD’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,198
Closed -$34.6K 3287
2024
Q1
$34.6K Hold
2,198
﹤0.01% 1736
2023
Q4
$35.5K Buy
2,198
+653
+42% +$8.33K ﹤0.01% 1639
2023
Q3
$19.7K Sell
1,545
-835
-35% -$11.5K ﹤0.01% 1858
2023
Q2
$33.5K Buy
2,380
+673
+39% +$9.63K ﹤0.01% 1640
2023
Q1
$26.4K Sell
1,707
-4
-0.2% -$67 ﹤0.01% 1714
2022
Q4
$28K Sell
1,711
-16
-0.9% -$260 ﹤0.01% 1642
2022
Q3
$32K Buy
1,727
+66
+4% +$1.04K ﹤0.01% 1517
2022
Q2
$22K Buy
1,661
+1,007
+154% +$11.1K ﹤0.01% 1731
2022
Q1
$6K Sell
654
-583
-47% -$4.96K ﹤0.01% 2447
2021
Q4
$12K Buy
1,237
+554
+81% +$10.4K ﹤0.01% 2057
2021
Q3
$23K Buy
+683
New +$21.8K ﹤0.01% 1706
2021
Q2
Sell
-85
Closed -$4K 3092
2021
Q1
$4K Buy
+85
New +$3.96K ﹤0.01% 2288
2020
Q3
Sell
-101
Closed -$6K 2789
2020
Q2
$6K Buy
101
+30
+42% +$1.6K ﹤0.01% 1763
2020
Q1
$3K Buy
+71
New +$3.94K ﹤0.01% 1873

Other funds holding DCPH

SignatureFD's DCPH Position: Q2 2024 in Review

SignatureFD sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 2,198 shares — an estimated $34.6K sold.

SignatureFD first reported a position in DCPH in Q1 2020 and held it in 14 quarters. The position peaked at $35.5K in Q4 2023. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • SignatureFD reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • SignatureFD sold 2,198 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $34.6K.
  • SignatureFD first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
  • SignatureFD's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $35.5K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on SignatureFD's 13F filing for Q2 2024, filed 29 Jul 2024.